Prof. Srivicha is an established malariologist, specializing in malaria treatment studies. She has extensive experience in conducting anti-malarial clinical drug trials. She is currently involved with the pharmaceutical development of the FDA-approved drug tafenoquine, a 3-day-dose radical cure for vivax malaria. Dr. Srivicha is a renowned expert in the clinical management of malaria, providing consultancy services that inform and influence Thai national malaria policy.